• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NEU 6.41% $15.27

NEUREN PHARMACEUTICALS LIMITED - Charts / Financials

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

refresh Created with Sketch. REFRESH
Last update - 15.59pm 27/09/2024 (20 minute delay) ?
Day
Open $14.35   Day High $15.27   Day Low $14.35
Daily Volume 579348
Bids   Sellers
Number Price Volume   Number Price Volume
1 $15.25 1000   5 $15.27 3990

Directors & Senior Management

Mr. Jonathan Charles Pilcher Chief Executive Officer, Managing Director, Executive Director
Ms. Lauren Frazer Chief Financial Officer, Company Secretary
Mr. Larry Glass Chief Science Officer
Dr. Clive Blower Vice President - Product Development
Mr. Gerry Zhao Vice President - Corporate Development
Ms. Liza Squires Chief Medical Officer
Mr. Patrick Donald Davies Non-Executive Independent Chairman of the Board
Ms. Dianne Angus Non-Executive Independent Director
Mr. Joseph Basile Non-Executive Independent Director
Dr. Jenny Lee Harry Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
$15.27
Change
0.920(6.41%)
Mkt cap ! $1.730B
Open High Low Value Volume
$14.35 $15.27 $14.35 $8.720M 579.3K

Buyers (Bids)

No. Vol. Price($)
1 1000 $15.25
 

Sellers (Offers)

Price($) Vol. No.
$15.27 3990 5
View Market Depth
Last trade - 16.10pm 27/09/2024 (20 minute delay) ?
Last
$15.26
  Change
0.920 ( 6.61 %)
Open High Low Volume
$14.40 $15.26 $14.36 89847
Last updated 15.59pm 27/09/2024 ?
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.
Fatal error: Uncaught ErrorException: session_write_close(): Failed to write session data using user defined save handler. (session.save_path: ) in /data/vhosts/test/hotcopper-git/upload/darkhorse/vendor/zendframework/zend-session/src/SessionManager.php:236 Stack trace: #0 [internal function]: Application\Service\AppManager::handlePhpError(2, 'session_write_c...', '/data/vhosts/te...', 236, Array) #1 /data/vhosts/test/hotcopper-git/upload/darkhorse/vendor/zendframework/zend-session/src/SessionManager.php(236): session_write_close() #2 [internal function]: Zend\Session\SessionManager->writeClose() #3 {main} thrown in /data/vhosts/test/hotcopper-git/upload/darkhorse/vendor/zendframework/zend-session/src/SessionManager.php on line 236